In the BioHarmony Drug Report Database

"Preview" Icon

Vismodegib

Erivedge (vismodegib) is a small molecule pharmaceutical. Vismodegib was first approved as Erivedge on 2012-01-30. It is used to treat skin neoplasms in the USA. It has been approved in Europe to treat basal cell carcinoma. The pharmaceutical is active against smoothened homolog. In addition, it is known to target Soluble cytochrome b562. Erivedge’s patents are valid until 2028-12-15 (FDA).

 

Trade Name

 

Erivedge
 

Common Name

 

vismodegib
 

ChEMBL ID

 

CHEMBL473417
 

Indication

 

basal cell carcinoma, skin neoplasms
 

Drug Class

 

Hedgehog signaling inhibitors

Image (chem structure or protein)

Vismodegib structure rendering